Author

Daniela Pugliese 1

1 Università Cattolica del S

Are we choosing wisely in inflammatory bowel disease care? The IG-IBD choosing wisely campaign

Marco Vincenzo Lenti, Alessandro Armuzzi, Fabiana Castiglione, Massimo Claudio Fantini, Gionata Fiorino, Ambrogio Orlando, Daniela Pugliese, Fernando Rizzello, Maurizio Vecchi, Antonio Di Sabatino

ASSESSMENT OF LOSS OF RESPONSE TO INFLIXIMAB THERAPY IN INFLAMMATORY BOWEL DISEASES USING ANTIBODIES TO INFLIXIMAB AND TROUGH LEVELS.

Luisa Guidi, Manuela Marzo, Carla Felice, Daniela Pugliese, Gianluca Andrisani, Giammarco Mocci, Olga Maria Nardone, Gian Lodovico Rapaccini, Alfredo Papa, Alessandro Armuzzi, Gian Lodovico Rapaccini

BIOLOGIC AGENTS IN IBD PATIENTS AFTER SOLID ORGAN TRANSPLANTATION DO NOT INCREASE THE RATES OF INFECTION OR ADVERSE EVENTS

Linda Cingolani, Greta Lorenzon, Fabiana Zingone, Renata D'Incà, Ilaria Marsilio, Brigida Barberio, Flavio Caprioli, Davide Giuseppe Ribaldone, Antonio Rispo, Agnese Miranda, Daniela Pugliese, Lorenzo Bertani, Ambrogio Orlando, Andrea Buda, Alberto Ferrarese, ANTONINO CARLO Privitera, Martina Gambato, Patrizia Burra, Edoa

COMBINATION THERAPY PREDICTS LONG-TERM MUCOSAL HEALING IN MODERATE-TO-SEVERE ULCERATIVE COLITIS TREATED WITH ANTI TNF-?

Daniela Pugliese, Pietro Manuel Ferraro, Carla Felice, Gian Lodovico Rapaccini, Alfredo Papa, Luisa Guidi, Alessandro Armuzzi

DEEP REMISSION IMPROVES CLINICAL OUTCOMES AFTER INFLIXIMAB DISCONTINUATION IN INFLAMMATORY BOWEL DISEASES

Carla Felice, Daniela Pugliese, Manuela Marzo, Gianluca Andrisani, Olga Maria Nardone, Alfredo Papa, Italo De Vitis, Gian Lodovico Rapaccini, Luisa Guidi, Alessandro Armuzzi

DUAL TARGETED THERAPY: A FUTURE STRATEGY FOR THE MANAGEMENT OF REFRACTORY INFLAMMATORY BOWEL DISEASE

Giuseppe Privitera, Sara Onali, Daniela Pugliese, Sara Renna, Edoardo Savarino, Anna Viola, Davide Giuseppe Ribaldone, Andrea Buda, Cristina Bezzio, Gionata Fiorino, Massimo Claudio Fantini, Franco Scaldaferri, Luisa Guidi, Silvio Danese, Antonio Gasbarrini, Ambrogio Orlando, Alessandro Armuzzi

Early Vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease

Luisa Guidi, Daniela Pugliese, Tommaso Panici Tonucci, Lorenzo Bertani, Francesco Costa, Giuseppe Privitera, Elisa Gremese, Barbara Tolusso, Clara Di Mario, Alfredo Papa, Antonio Gasbarrini, Gian Lodovico Rapaccini, Alessandro Armuzzi

EFFECTIVENESS AND SAFETY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB FORMULATION IN INFLAMMATORY BOWEL DISEASE PATIENTS IN CLINICAL REMISSION

Laura Parisio, Carlo Romano Settanni, Daniele Napolitano, Simone Varca, Elisa Schiavoni, Lucrezia Laterza, Loris Riccardo Lopetuso, Marco Pizzoferrato, Stefano Bibbò, Norma Alfieri, Luisa Guidi, Alfredo Papa, Antonio Gasbarrini, Alessandro Armuzzi, Daniela Pugliese, Franco Scaldaferri

EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN A MATCHED COHORT OF ELDERLY AND YOUNG IBD PATIENTS – LIVE STUDY-GROUP

Giuseppe Privitera, Daniela Pugliese, Alessandro Armuzzi

EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN A MATCHED COHORT OF ELDERLY AND YOUNG IBD PATIENTS – LIVE STUDY-GROUP

Daniela Pugliese

Item 1 - 10 / 31
1
2 3 4